Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 19.10.2026 3 Aliment Pharmacol Ther 1 Clin Gastroenterol Hepatol 1 Clin Res Hepatol Gastroenterol 1 Drugs 1 Gastroenterology 6 Inflamm Bowel Dis 3 J Crohns Colitis 1 N Engl J Med 3 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. CARBALLO-FOLGOSO L, Duque Alcorta JM, Varela P, Suarez A, et al
   Editorial: How Can We Best Detect Frailty in Older Patients With Inflammatory Bowel Disease? Authors'Reply.
   Aliment Pharmacol Ther. 2026 Oct 16. doi: 10.1111/apt.71054.
   PubMed        
   
   
2. SATTAYALERTYANYONG O, Nugent Z, Bernstein CN
   Letter: From End-Stage Renal Disease Association to Risk-Stratified Kidney Surveillance in Inflammatory Bowel Disease-Authors' Reply.
   Aliment Pharmacol Ther. 2026 Oct 12. doi: 10.1111/apt.71050.
   PubMed        
   
   
3. GARRE A, Nunez Ortiz A, Rubio S, Diz-Lois Palomares MT, et al
   Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five-Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease.
   Aliment Pharmacol Ther. 2026 Oct 11. doi: 10.1111/apt.70987.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

4. BALMER C, Agrawal M, Hansen AV, Torres J, et al
   Early-life animal exposure was not associated with risk of inflammatory bowel disease: a nationwide birth cohort study.
   Clin Gastroenterol Hepatol. 2026 Oct 13:S1542-3565(26)00757.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

5. JIANG M, Meng Q, Xue L
   Separating Prognostic Association from Treatment-Effect Modification of a Baseline Mucosal Inflammatory-Response Score in Ulcerative Colitis Biologic Trials.
   Clin Res Hepatol Gastroenterol. 2026 Oct 16:102943.
   PubMed         Abstract available
   
   

   
   Drugs

6. SAREEN J, Prichodko M, Graff LA, Keshavarzian A, et al
   Fatigue in Inflammatory Bowel Disease: The Role of Drug Therapy Within a Holistic Management Framework.
   Drugs. 2026 Oct 15. doi: 10.1007/s40265-026-02397.
   PubMed         Abstract available
   
   

   
   Gastroenterology

7. CHANDRA J, Czarnecki D, Mukherjee PK, West GA, et al
   Myofibroblast Derived Transglutaminase 2 Activity is Upregulated in Stricturing Crohn's Disease and its Inhibition Exerts Anti-Fibrotic Properties.
   Gastroenterology. 2026 Oct 13:S0016-5085(26)07334.
   PubMed         Abstract available
   
   

   
   Inflamm Bowel Dis

8. ALQINAI B, Gayam S, Hadam-Veverka J
   GLP-1 receptor agonists and symptomatic remission in ulcerative colitis: A credible signal that welcomes prospective study.
   Inflamm Bowel Dis. 2026 Oct 16:izag216. doi: 10.1093.
   PubMed        
   
   
9. AGARGUN BF, Isik B, Bardak AE, Cavus B, et al
   GLP-1 receptor agonists and symptomatic remission in ulcerative colitis: how large an effect is credible?
   Inflamm Bowel Dis. 2026 Oct 15:izag215. doi: 10.1093.
   PubMed        
   
   
10. SCHELL T, Kalapala J, Armwald B, Turunen A, et al
    Lower rates of endoscopic remission among incarcerated patients with inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Oct 14:izag211. doi: 10.1093.
    PubMed        
    
    
11. OLSEN BC, Hagen M, Opheim R, Kristensen VA, et al
    Health-related quality of life after diagnosis of ulcerative colitis and Crohn's disease: 3-year trajectories and factors associated with clinically meaningful improvement (the IBSEN III cohort).
    Inflamm Bowel Dis. 2026 Oct 14:izag196. doi: 10.1093.
    PubMed         Abstract available
    
    
12. GOYAL MK, Bishu S
    The right dose for the right patient: Toward precision infliximab therapy in acute severe ulcerative colitis.
    Inflamm Bowel Dis. 2026 Oct 14:izag204. doi: 10.1093.
    PubMed        
    
    
13. IVANOV MI, Blair JE, Ramos GP
    Screening and management of coccidioidomycosis in patients with inflammatory bowel disease on immunosuppressive therapies.
    Inflamm Bowel Dis. 2026 Oct 13:izag197. doi: 10.1093.
    PubMed        
    
    

    
    J Crohns Colitis

14. SINGH A, Garg A, Bhardwaj A, Singh D, et al
    Tofacitinib 20 vs 30 mg in acute severe ulcerative colitis: a double-blind randomized controlled trial.
    J Crohns Colitis. 2026;20:jjag147.
    PubMed         Abstract available
    
    
15. SIEGMUND B, Crosby CM, Ryan RD, Smith J, et al
    Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data.
    J Crohns Colitis. 2026;20:jjag159.
    PubMed         Abstract available
    
    
16. COOPER S, Watermeyer G, Levin D, Mhlaba Z, et al
    Challenges and opportunities facing inflammatory bowel disease in Sub-Saharan Africa: towards a contextually relevant research and practice agenda.
    J Crohns Colitis. 2026;20:jjag135.
    PubMed         Abstract available
    
    

    
    N Engl J Med

17. ABREU MT, Siegmund B, Surace L, Erondu N, et al
    Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.
    N Engl J Med. 2026;395:1495-1504.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

18. RADFORD SJ, Olsen BJ, Noor NM, Crooks CJ, et al
    Defining and measuring disease burden in Crohn's disease: a systematic literature review.
    Scand J Gastroenterol. 2026 Oct 16:1-12. doi: 10.1080/00365521.2026.2745974.
    PubMed         Abstract available
    
    
19. VILLUMSEN M, Thomsen T, Poulsen A, Jess T, et al
    Physical activity in individuals with inflammatory bowel disease: a Danish population-based repeated cross-sectional study.
    Scand J Gastroenterol. 2026 Oct 14:1-10. doi: 10.1080/00365521.2026.2745977.
    PubMed         Abstract available
    
    
20. WOD M, Norgard BM, Sorensen E, Nielsen J, et al
    Time trends in patients with ulcerative colitis and crohn's disease not receiving IBD-specific pharmacological treatment within one and three years of diagnosis - a nationwide cohort study.
    Scand J Gastroenterol. 2026 Oct 12:1-9. doi: 10.1080/00365521.2026.2745982.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum